Director, Executive Chairman, 10% Owner · BlossomHill Therapeutics, Inc. · Common Stock
Side
C
Value
—
Shares
113.4K
Price
—
Executed
Aug 10, 2026
Disclosed
Aug 10, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Aug 10 executedAug 10, 2026 disclosed
BLSM · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Derivative conversion — administrative, little informational value
Relative size+5 / 25
No reported dollar value · 7.1% of prior position
Filing timing0 / 15
Disclosed 0 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Li Yishan filed this Form 4 reporting a derivative conversion of BLSM on Aug 10, 2026. It became public on Aug 10, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, Executive Chairman, 10% Owner
Li Yishancik:0001772233
Issuer
BlossomHill Therapeutics, Inc.cik:0001839970
Revision history · 0
No field has changed since this record was first ingested.
